In today's society, it is more and more necessary to use business plans, which can help entrepreneurs understand themselves more clearly. Do you know the format of business plan? The following is a bio-related innovation and entrepreneurship plan I compiled for you, for reference only. Welcome to reading.
Biology 1 Innovation and Entrepreneurship Plan I. Project Introduction:
1. Definition: biopharmaceuticals refer to a kind of products extracted from organisms, biological tissues, cells and body fluids for prevention, treatment and diagnosis by using the research results of microbiology, biology, medicine and biochemistry and the scientific principles and methods of microbiology, chemistry, biochemistry, biotechnology and pharmacy.
2. Raw materials: The raw materials of biopharmaceuticals are mainly natural biological materials, including microorganisms, human bodies, animals, plants and marine life. With the development of biotechnology, purposefully manufactured biological raw materials have become the main source of biopharmaceutical raw materials.
3. Product ingredients: vitamins, erythromycin, clindamycin, etc. Penicillin, streptomycin and gentamicin for injection are fermented by different microorganisms. The vast majority of antibiotics used in medicine come from microorganisms, and each product has strict production standards. Predicting the research progress of biopharmaceuticals will be widely used to treat cancer, AIDS, coronary heart disease, anemia, dysplasia, diabetes and other diseases.
Second, the service introduction:
1. Customers: demanders and direct users of medical institutions such as hospitals and biopharmaceutical products.
2. Service organizations: Specialized service organizations should be set up, such as specialized consultation and after-sales service organizations in hospitals and residential areas.
3. Service personnel: train a special team, mainly including sales personnel, drug experts, lawyers, managers, information collectors, etc. , and pay attention to the division of labor, coordination and unity.
4. Service spirit: form a unique service culture, establish a first-class service image, and adhere to the purpose of service first.
5. Service content: R&D departments should focus on developing new technologies and producing new products to meet the new needs of consumers; The consulting organization is mainly responsible for answering the information about the use of drugs by doctors, patients and residents in residential areas, promoting new products and collecting their higher demand information, which is convenient for the company to develop and promote new drugs and further expand the product market; After-sales service agencies are mainly responsible for collecting the drug effect and feeding it back to the headquarters and R&D departments, and at the same time dealing with the analysis and investigation of some after-sales problems to try their best to reduce the adverse effects.
6. Service mode: service personnel establish two-way contact with consumers, strengthen communication and supervise each other in a harmonious atmosphere.
Third, the market analysis and forecast:
1. Market environment analysis: biopharmaceutical camp is huge and developing rapidly. At present, half of the drugs in the world are biosynthesized, especially when synthesizing drugs with complex molecular structure, which is not only simpler than chemical synthesis, but also has higher economic benefits. In the past half century, a series of breakthrough applications of microbial transformation in drug development have created great medical value and economic benefits for the pharmaceutical industry.
(1) Political and legal environment: biopharmaceuticals are highly patented because of their high technical content, so biopharmaceuticals have high legal barriers and are difficult to enter.
(2) Economic environment: With the rapid development of human society and unprecedented economic development, people can have more economic capacity to invest in medical care. At the same time, with the rapid development of science and technology, biopharmaceutical technology will gradually mature and update. Therefore, from the general trend, biopharmaceuticals will have a broad market demand.
(3) Social culture: With the improvement of people's living standards, people pay more attention to their own health problems, so biopharmaceuticals can meet this demand well, and there is no substitute.
(4) Technical analysis: The technical requirements of biopharmaceuticals are very high, which can not only prevent new competitors from joining, but also pre-empt the existing industry competition.
2. Market demand analysis: Due to the wide variety of biopharmaceuticals, the market demand for biopharmaceuticals is broad and diversified. For example, therapeutic drugs mainly meet the treatment needs of patients, while health drugs are promoted and used for the vast number of people with health awareness. At present, many people have the habit of using drugs more or less, and there are usually many drugs in reserve at home. As far as people's overall health status is concerned, many people are in the sub-health stage, and with the decline of people's overall physical fitness, people have become dependent on drugs to some extent. Whether it is used to treat diseases or to prevent diseases or other unhealthy conditions, people will choose to use drugs or other health care products, so biopharmaceutical products will also appear in a reciprocal way. In the long run, with the progress of human society and the rapid development of economy, people will pay more and more attention to their own health, and with the improvement of people's life expectancy, the aging population will become more and more prominent, and the demand for biopharmaceutical products by the elderly will be a great demand. In addition, with the development of science and technology, people's demand for biopharmaceutical products will be continuously met. Based on the above analysis, we can draw a conclusion that the biopharmaceutical market has great potential and the possibility of expansion.
3. Analysis of market competition: From the characteristics of biopharmaceutical industry, it can be seen that this industry belongs to technology-intensive industry and has the characteristics of capital-intensive industry, so the market competitiveness of biopharmaceutical enterprises is mainly reflected in enterprise research and development, capital and scale. Let me analyze these three aspects. First of all, technology is the foundation of biopharmaceutical enterprises. Without advanced and constantly updated technology, it is difficult to gain a foothold in this industry, and even a temporary survival cannot get rid of the fate of being eventually eliminated. When it comes to technology, we can't help talking about innovation. Biopharmaceutical enterprises need innovative ability and a group of innovative R&D talents and teams. Then, biopharmaceutical enterprises should have sufficient capital flow and must ensure the operation of R&D funds. If you don't have enough money, you may be limited in the competition. Finally, the scale of biopharmaceutical enterprises is a very important issue, because it is not only the result of the first two, but also can promote its better development and the realization of its goals. The scale of enterprises should be moderate, not only to ensure normal operation, but also to have the possibility of further development. Looking at the enterprises in biopharmaceutical industry, the overall competition is fierce, but they all have certain benefits. These enterprises are trying to make themselves stand out, so they are all working hard in these three aspects, hoping to make a breakthrough.
Fourth, marketing strategy.
1. sales channel: principle (make different sales strategies and plans according to different products. The framework of marketing system is to establish marketing system by object and product, and form a marketing network covered by matrix. )
(1) For therapeutic and diagnostic drugs, the company should promote them to major hospitals and other medical institutions and major pharmacies, and make appropriate feedback and improvement through the use of patients.
⑵ For health care products, the company should enter the health care products market and promote them in major supermarkets and other retailers through distribution.
2. Sales plan: (1) Establish a strong marketing team. We attach importance to cultivating a team of high-quality sales engineers and marketing managers with team spirit, and to discovering and cultivating strategic marketing management talents and international marketing talents. It is necessary to establish a marketing team with long-term goals, which is motivated and driven by the same career, responsibility and honor.
(2) The overall discussion and formulation of the marketing plan.
(3) implementation plan.
(4) Conduct market research, collect sales information, summarize the advantages and disadvantages of the marketing plan, and discuss the overall improvement.
3. Customer relationship: We should ensure communication and contact with major customers and develop relationships with small and medium-sized customers.
(1) The company should keep close contact with its major customers, not only in business dealings, but also in deeper relationships, so as to ensure the company's sales performance and profits.
The company should pay attention to keep in touch with small and medium-sized customers. Although it is not a big customer at present, in the long run, the company will open up markets and broaden its business in the future. These customers have great development potential.
Verb (abbreviation for verb) company strategy and management
1. Corporate culture: resources will be exhausted, and only culture will be endless. All products are created by human wisdom. Spirit can be transformed into matter, and material civilization is conducive to consolidating spiritual civilization. We adhere to the policy of promoting material civilization with spiritual civilization. The culture here includes not only knowledge, technology, management and sentiment ... but also all intangible factors that promote the development of productive forces.
2. Enterprise strategy: it is positioned in the relevant diversification strategy, that is, biopharmaceutical enterprises should not only have the core competitiveness of biopharmaceutical products, but also broaden the development space. Comparing several enterprise strategies, the related diversification strategy is a better enterprise strategy. First, you can avoid entering unfamiliar industries. Then, the core industries can be supplemented; Finally, the risk of related diversification strategy is relatively small.
3. Organizational structure: The basic organizational structure of the company will be a two-dimensional structure: business divisions divided by strategic undertakings and regional companies divided by regions. The Division undertakes the responsibilities of development, production, sales and customer service within the business scope specified by the Company; Regional companies effectively use the company's resources and operate in the regional market designated by the company. Division and regional companies are profit centers and bear actual profit responsibilities. The company's management resources, research resources, production management resources, market resources, financial resources, human resources and information resources are the public resources of the company. In order to improve the efficiency of the use of public resources, auditing is necessary. Organize the corresponding departments according to the principle of functional specialization, and form the main body of the company's organizational structure.
4. Performance appraisal and reward and punishment system:
The company implements a strict performance appraisal system, which not only requires the company management to assess and comment on employees, but also listens to employees' own introspection and evaluation. The performance appraisal of employees should not only be linked to their work performance, but also fully consider their own abilities and consumers' evaluation of employee services.
The reward and punishment system should be clear, selfless, fair, just and open, and listen to the opinions of employees and management. At the same time, the forms of rewards and punishments require diversification, and rewards and punishments are carried out according to different behaviors.
5. Personnel training: regularly train employees and managers to improve their quality and make better contributions to the company.
Financial analysis of intransitive verbs
1. Initial cost
(1) Purchase of plant and production line: 5 million.
(2) Recruiting employees: 2 million.
(3) R&D personnel: 2 million.
④ Liquidity: 5 million.
2. Financial budget: there are financial personnel to do statistics.
3. Investment analysis: The basic orientation is to produce health care products. When production reaches a certain scale, we will invest in other biopharmaceutical products.
Seven. Risk analysis
Because this industry has high requirements for technology and capital, it has been squeezed out by other peer companies, and some details are not clear. Financial problems may bring risks to investing in this industry.
Eight. Legal analysis
Technology patent is a very important issue. From the beginning, we should avoid falling into the legal whirlpool of patent theft, strictly manage production, prevent product quality problems and maintain a good corporate image.
Innovation and Entrepreneurship Plan under the Background of Biology 2 Industry;
Biochip, known as the most promising new technology to change human life in 2 1 century, has not been widely used because of its high manufacturing cost and low precision, and our project has solved the key problems in this industry.
Technical advantages:
The biochip spotter was developed by the research group of Professor Tian Zhaowu, an academician of China Academy of Sciences and the State Key Laboratory of Physical Chemistry of Solid Surfaces of Xiamen University, and has obtained the national invention patent for manufacturing biochips (patent number: ZL02 126729. 1+0). Its core component is: integrated sample block.
The powerful advantages of this product are:
1, accuracy: high sampling accuracy, which greatly improves the detection accuracy of biochip.
2. Efficiency: no pre-sampling, and the integrated sampling block used is a disposable product, which does not need cleaning, thus avoiding cross-contamination; Using micro-liquid transfer technology, the reagent consumption is very small.
3. Price: Compared with the million yuan price of traditional instruments, a steel needle costs several thousand yuan, a basic point sampler only costs 300,000 yuan, and an integrated sampling block only costs 1 1,000 yuan, which can replace dozens to hundreds of steel needles in traditional processes as needed, greatly reducing the manufacturing cost of biochips.
Competitive advantage:
1. Advanced technology: After years of research and development, our products are highly original and leading in China.
2. Strong R&D capability: Relying on the State Key Laboratory of Physical Chemistry of Solid Surfaces of Xiamen University, we have strong scientific research strength.
3. Perfect service system: including establishing an information platform, implementing training plans, and establishing offices, technical service centers and hotlines.
Market prospect:
International survey shows that the world biochip market is growing at a rate of 20% every year, which is higher than that of China due to the influence of policies and economy. Therefore, the market prospect is broad. When our technology is widely used, the medical chip market will really open, the industry will mature and the market will show explosive growth. In the market survey, 80% of the respondents expressed their willingness to try out the basic products, and we are discussing the trial production with Shenzhen Yaneng Company.
Investment analysis:
The net present value of the project is 2.06 million yuan (R= 15%, n=5 years), the internal rate of return is 29%, and the payback period of investment is only about 4 years. For venture capitalists, they only need to invest 6.5438+0.575 million yuan at the beginning of the project, but they can get a total dividend of 2.69 million yuan in five years, and the share of net assets at the end of the period is as high as 2.98 million yuan; High rate of return greatly meets the requirements of low input and high return.
;